- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07705204
Adverse Events Among Hospitalized Patients in China
Adverse Events Among Hospitalized Patients: A Multicenter Evaluation of Four Detection Methods
The goal of this observational study is to learn about the incidence and characteristics of adverse events (AEs) among hospitalized patients in China and to compare 4 commonly used methods for detecting these events. The main questions it aims to answer are:
How common are AEs among hospitalized patients, and what are their characteristics (types, severity, and preventability) in China? How do 4 commonly used methods, including the Harvard Medical Practice Study (HMPS), Global Trigger Tool (GTT), Patient Safety Indicators (PSIs), and incident reporting systems (IRSs), compare in detecting AEs? Researchers review randomly selected medical records from 5 hospitals in China to identify AEs, assess their type, severity, and preventability, and evaluate the performance of the 4 detection methods.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- age ≥18 years and a length of stay of at least 24 hours
Exclusion Criteria:
- Patients admitted primarily for psychiatric disorders, palliative care, or rehabilitation were excluded.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse event incidence
Tijdsspanne: During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge.
|
The proportion of admissions with at least one adverse event.
|
During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Types of adverse event
Tijdsspanne: During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
|
|
Preventability of adverse event
Tijdsspanne: During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
Adverse event with 6-point Likert scale scores ≥4 were considered preventable.
|
During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
|
Severity of adverse events
Tijdsspanne: During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
Severity was graded using the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) classification.
|
During the index admission, including review of relevant prior hospitalization records and all available records through 30 days after discharge
|
|
Sensitivity of adverse event detection methods
Tijdsspanne: After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
Admission-level sensitivity was calculated for the Harvard Medical Practice Study (HMPS), Global Trigger Tool (GTT), Patient Safety Indicators (PSIs), and incident reporting systems (IRSs).
|
After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
|
Specificity of adverse event detection methods
Tijdsspanne: After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
Admission-level specificity was calculated for the Harvard Medical Practice Study (HMPS), Global Trigger Tool (GTT), Patient Safety Indicators (PSIs), and incident reporting systems (IRSs).
|
After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
|
Positive predictive value (PPV) of adverse event detection methods
Tijdsspanne: After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
Admission-level positive predictive value (PPV) was calculated for the Harvard Medical Practice Study (HMPS), Global Trigger Tool (GTT), Patient Safety Indicators (PSIs), and incident reporting systems (IRSs).
|
After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
|
Negative predictive value (NPV) of adverse event detection methods
Tijdsspanne: After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
Admission-level negative predictive value (NPV) was calculated for the Harvard Medical Practice Study (HMPS), Global Trigger Tool (GTT), Patient Safety Indicators (PSIs), and incident reporting systems (IRSs).
|
After completion of AE screening, adjudication, and re-review of randomly sampled screen-negative admissions
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- I-25PJ1969
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .